Ligand validation:8ECF

TSL: TRANS-ENAMINE INTERMEDIATE OF SULBACTAM

TSL is a Ligand Of Interest in 8ECF designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
8ECF_TSL_D_302	14%	52%	0.324	0.875	0.91	0.93	-	1	1	0	100%	1
8ECF_TSL_B_302	9%	64%	0.351	0.85	0.9	0.48	-	-	0	0	100%	1
8ECF_TSL_A_302	9%	60%	0.357	0.856	0.85	0.7	-	-	1	0	100%	1
8ECF_TSL_C_302	5%	49%	0.458	0.86	0.92	1.05	-	1	0	0	100%	1
7A72_TSL_A_501	73%	44%	0.106	0.931	1.46	0.72	2	-	1	0	100%	1
8GCX_TSL_B_302	63%	5%	0.181	0.977	1.69	3.68	2	3	2	0	100%	1
6H2K_TSL_B_501	60%	21%	0.12	0.906	1.23	2.05	-	2	3	0	100%	1
8EC4_TSL_A_302	31%	5%	0.209	0.878	1.66	3.54	2	1	2	0	100%	0.837
8EBR_TSL_B_302	25%	5%	0.244	0.882	1.67	3.65	2	3	0	0	100%	1
6J2B_TSL_A_301	48%	55%	0.141	0.882	1.38	0.4	1	-	1	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.